AnaptysBio (ANAB) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

AnaptysBio

NasdaqGS•Healthcare•Biotechnology

$48.28-0.36(-0.01%)Market open

Market Cap

$1.35B

P/S

5.8x

P/B

105.6x

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

How this company scores

GoodMetricSide Score: 62/100

Strongest: Growth (21/25); weakest: Cash & Earnings Quality (12/25).

Profitability14/25

Growth21/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality12/25

Strengths

Growing revenueLong cash runwayInterest easily coveredProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 43.5x5y range 43.5x – 43.5x

P/S · 5.8x5y range 2.5x – 83.8x

Currently near its 20-quarter median.

P/B · 105.6x5y range 0.9x – 105.6x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.35B

Metrics at a Glance

as of March 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $232.39M
Q. Revenue: $25.56M
TTM EBITDA: $41.34M
TTM Op. Income: $40.80M
Q. Op. Income: $-34.64M
TTM Net Income: $-26.79M
Q. Net Income: $-52.88M
EPS: $-1.84
Shares Out.: $28.69M

$232.39M in TTM revenue grew 107.7% YoY, reaching $25.56M last quarter. TTM EBITDA of $41.34M and TTM operating income of $40.80M show growth is flowing through to the bottom line. However, net income is negative at $26.79M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 108% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -135.0%
Op. Margin: -135.5%
Net Margin: -206.9%

Op. margin of -135.5% is down 36.4% YoY — costs are rising relative to revenue. Net margin at -206.9% Over the past year, operating margin is down 37% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 5.8x
P/B Ratio: 105.6x

P/S of 5.8x and P/B of 105.6x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $329.68M
Cash: $248.47M
Long-Term Debt: N/A
Book Value: $12.75M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-25.92M
TTM Free Cash Flow: $4.41M
FCF Margin: 1.9%
FCF / Net Income: -0.2

TTM FCF of $4.41M on $-25.92M in operating cash flow. The FCF / Net Income ratio of -0.2x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is up 104% — a weakening trend.